TriangleBalstilimab (BAL) (NCT07550088)
Balstilimab (BAL) trial for Colorectal Cancer Metastatic (NCT07550088). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with microsatellite-stable, mismatch-repair-proficient colorectal cancer and active liver metastases after specified chemotherapy. Prior immunotherapy is excluded; at least one measurable liver lesion is required.
The idea: balstilimab and botensilimab block PD-1 and CTLA-4 immune brakes. Donor-derived agenT-797 natural killer T cells are added to promote anticancer immunity. All patients receive the combination, with two cell infusions and different antibody schedules. Researchers assess tumor shrinkage and side effects.
This phase 2 study plans 17 patients. Darren Sigal sponsors it at Scripps in La Jolla, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.